Sania Therapeutics is a ground-breaking biotechnology company pioneering new approaches for targeted and controllable gene therapies to treat prevalent disorders. Sania’s approach harnesses neural circuits as a gateway to disease states. Their research and development is centred around a human-first approach to ultimately build more translatable, safer and cost-effective AAV gene therapies capable of treating millions of patients. Sania is based in London, UK. For more information visit www.saniarx.com.